Understanding how gene therapy affects blood cancer treatment
Official title: Comprehensive Characterization of LVV Integration and Impact on Host Cell Biology using Novel Genomic Technologies
Funded at University of Louisville · NIH-10998612 · Data updated 2026-11-12
This study is looking at how a special type of gene therapy, used to treat blood cancers like acute lymphoblastic leukemia, affects the way our cells work and how they might cause side effects, with the hope of making these treatments safer and more effective for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $35,822 |
| NIH project number | 1F31AI186545-01 |
| Project ID | NIH-10998612 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute lymphoblastic leukemia or other B cell malignancies who are considering or have undergone CAR T-cell therapy.
✕Less likely to help
Patients with solid tumors or those not receiving CAR T-cell therapies may not benefit from this research.
What this research studies
This research investigates the integration of lentiviral vectors (LVVs) into host DNA and their impact on cellular biology, particularly in the context of treating blood cancers like acute lymphoblastic leukemia. By utilizing novel genomic technologies, the study aims to characterize how these vectors influence gene expression and alternative splicing patterns in patients receiving CAR T-cell therapies. The goal is to better understand the mechanisms behind potential adverse effects, such as cellular transformation, which have been linked to these therapies. This research could provide insights that improve the safety and efficacy of gene therapies for blood cancers.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective gene therapies for patients with blood cancers.
How similar studies have gone: Previous research has shown promise in understanding LVV integration and its effects, but this specific approach is novel and aims to address recent safety concerns.
Where this research is happening
-
University of Louisville
Louisville, United States Active
Researchers
- Principal investigator: Kaiser, Catherine — University of Louisville
- Study coordinator: Kaiser, Catherine
Related research
Other NIH-funded projects on the same topics.
-
Gastric rhythm map to understand stomach problems using a new noninvasive tool
A new noninvasive body surface mapping method is being tested to see if abnormal stomach electrical rhythms explain chronic stomach problems like functional dyspepsia and persistent nausea.
-
Novel antivirals for alphavirus arthritis
A research team is refining a promising antiviral compound to treat alphavirus infections that cause arthritis, with a focus on Chikungunya and related viruses.
-
Linking heavy metal exposure to a tougher breast cancer type (TNBC)
Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.
-
Cardiac safety of flavored e-cigarette aerosols in adults
A pharmacist or clinician would test how inhaling flavored e-cigarette aerosols affects heart rhythm in adults to see if flavors raise the risk of heart problems.
-
Biomedical Research Facilities to Expand Precision Medicine in Kentucky
A large NIH grant aims to renovate and expand a shared precision medicine center in Kentucky to speed up research that could improve health for people in Appalachia and surrounding areas.
-
Rac-enhanced CAR-Macrophages against TNBC
A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.